Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: A 10-year epidemiological study by Parker MJS et al.
Concise Report
Increasing incidence of adult idiopathic
inflammatory myopathies in the City of Salford, UK: a
10-year epidemiological study
Matthew J. S. Parker1,2, Alexander Oldroyd 2,3, Mark E. Roberts4,
William E. Ollier1,2, Robert P. New5, Robert G. Cooper5,6, Hector Chinoy 1,2
for the UKMYONET consortium
Abstract
Objectives. The aim was to identify and characterize all incident adult cases of idiopathic inflamma-
tory myopathies (IIM) between 1 January 2007 and 31 December 2016 in the City of Salford, UK.
Methods. Adults first diagnosed with IIM within the study period were identified by: a Salford Royal
NHS Foundation Trust (SRFT) inpatient episode IIM-specific ICD-10 coding search; all new patient
appointments to SRFT neuromuscular outpatient clinics; and all Salford residents enrolled within the
UKMYONET study. All patients with definite IIM by the 2017 EULAR/ACR classification criteria were
included, as were probable cases if consensus expert opinion agreed. Cases were excluded if
<18 years of age at disease onset, if they did not meet probable criteria or when probable but expert
opinion concluded a non-IIM diagnosis.
Results. The multimodal case ascertainment identified 1156 cases which, after review and application
of exclusion criteria, resulted in 32 incident cases during the study period. Twenty-three of 32 were
female, with a mean age of 58.1 years. The mean incidence of adult IIM was 17.6/1 000 000 person
years, and higher for females than for males (25.2 vs 10.0/1 000 000 person years, respectively). A sig-
nificant incidence increase over time was apparent (13.6 vs 21.4/1 000 000 person years; P¼ 0.032).
Using EULAR/ACR classification criteria, the largest IIM subtype (21/32) was PM, followed by DM
(8/32), IBM (2/32) and amyopathic DM (1/32). Expert opinion subtype differed from EULAR/ACR classi-
fication criteria in 19/32 cases.
Conclusion. The incidence of adult IIM in Salford is 17.6/1 000 000 person years, higher in females,
and is increasing over time. Disagreement exists between EULAR/ACR-derived and expert opinion-
derived IIM subtype assignments.
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Introduction
The idiopathic inflammatory myopathies (IIM) represent
a spectrum of rare immune-mediated syndromes usually
characterized by inflammation in skeletal muscle [1].
Studying the epidemiology of rare conditions can assist
in the identification of risk factors, disease associations
and temporal trends. Interrogation of differing geograph-
ically and genetically diverse populations can help to
construct a more complete picture of underlying disease
patterns.
A number of UK centres have contributed to national
and international IIM research collaborations, but to date
there has been no published report detailing the inci-
dence or prevalence of adult IIM in the UK or to estab-
lish the relative proportion of the varying clinical
subtypes. Moreover, previous international studies have
focused on specific IIM subtypes, such as IBM or
immune-mediated necrotizing myopathy (IMNM), are
historic, were undertaken before recent developments in
our understanding of the range of IIM subtypes and
used widely varying methodologies and case acquisition
strategies [2, 3].
The recently published combined EULAR/ACR classifi-
cation criteria for adult and juvenile IIM represent poten-
tial progress in identifying IIM and various disease
subtypes [4]. We present here the first epidemiological
study to use these new criteria as part of disease verifi-
cation. Briefly, the criteria comprise 16 variables, each
with a corresponding weighted score. The gross sum of
these scores can be used directly or converted into a
probability (as a percentage) of an IIM diagnosis. The
proposed cut-points for the diagnosis of a definite,
probable and possible IIM are 90% (score 7.5 with-
out biopsy; 8.7 with biopsy), 55–89% (5.5–7.4 without
biopsy; 6.7–8.6 with biopsy) and 50–54% (score 5.3–5.4
without biopsy or 6.5–6.6 with biopsy), respectively. A
second function is in the identification of one of four IIM
disease subtypes, namely PM, DM, IBM or amyopathic
DM (ADM).
The aim of this study was to identify all incident cases
of IIM between 1 January 2007 and 31 December 31
2016 in the City of Salford, UK. A secondary aim was to
characterize incident cases using clinical and laboratory
data and, specifically, to compare the utility of the
EULAR/ACR classification criteria against diagnosis
made by expert opinion.
Methods
This work represents part of a national quality improve-
ment project aimed at identifying IIM cases for
specialized disease commissioning, because accurate
incidence data will inform future service planning. Given
this context, approval for the conduct of the project was
granted without a recommendation to seek more formal
ethics authorization, in keeping with local policy.
Denominator population
Salford is a City within Greater Manchester, UK, compris-
ing a spectrum from densely populated areas to open ru-
ral space, whose mean annual population is publically
available, stratified by age and sex. We excluded persons
<18 years old in calculations of incidence. Salford Royal
NHS Foundation Trust (SRFT) provides tertiary neuromus-
cular services for adults with an IIM in North West
England, UK. SRFT is ideal to undertake an IIM epidemio-
logical study as the sole provider of services for adult
patients with IIM within our study area, with a longstand-
ing status as a specialist neuromuscular service provider
and with advanced information technology systems. It is
routine practice locally for all cases of suspected IIM to
be referred to the neuromuscular service even if, for ex-
ample, they have predominantly or exclusively extramus-
cular IIM manifestations.
Case definition
Adults diagnosed with IIM and resident in Salford be-
tween 1 January 2007 and 31 December 2016 were eli-
gible. Using the EULAR/ACR classification criteria, all
cases with definite IIM (90% probability, corresponding
to a total aggregate score of 7.5 without muscle bi-
opsy findings or 8.7 with biopsy data) were included,
as were those with probable IIM (55–90% probability;
aggregate score 5.5 without biopsy or 6.7 with bi-
opsy) if the opinion of attending tertiary neuromuscular
experts was of an IIM diagnosis [4]. The independent
opinion on the certainty of an IIM diagnosis was
obtained from at least two investigators in this instance.
Cases were excluded if they were <18 years of age at
disease onset, if their case did not meet probable
criteria or if they met probable criteria but the consen-
sus expert opinion was of a diagnosis other than IIM.
The EULAR/ACR criteria used with or without the deci-
sion tree identify the specific IIM subtypes of PM, DM, IBM
Key messages
. The mean incidence of adult idiopathic inflammatory myopathies in Salford, UK, is 17.6 (15.2–20.0)/1 000 000
person years.
. The incidence of adult idiopathic inflammatory myopathies increased significantly over the duration of the study.
. There is disagreement between EULAR/ACR classification criteria and expert opinion with regard to idiopathic
inflammatory myopathy subtypes.
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and ADM or indicate if a case is unclassifiable, in which
case the subtype determined by the decision tree would
be PM by default unless a pattern of weakness suggestive
of IBM is present. Biopsy data were always included where
available. Although not standardized in formal criteria to the
same extent, further IIM subtypes are well described and
include the anti-synthetase syndrome (characterized by
the presence of one of the eight described anti-tRNA-
synthetase antibodies), IMNM (characterized by specific bi-
opsy and/or autoantibody status) and overlap myositis
(OM; where a specific associated connective-tissue disor-
der is present together with myositis, such as MCTD, SSc
or RA) [1, 5]. In every case, the expert opinion of diagnostic
subtype was recorded in addition to the subtype derived
by the EULAR/ACR classification criteria.
Case identification
Three stages of overlapping case ascertainment were
used in SRFT. First, an ICD-10 coding search consis-
tent with a recently published study was performed
for all inpatient hospital episodes related to IIM at
SRFT [6]. Second, all new patients referred to SRFT
neuromuscular outpatient clinics were identified.
Third, all persons enrolled in the UKMYONET data-
base, a national research collaboration involving mul-
tiple centres around the UK, and enrolling IIM patients
resident in Salford were identified. These data sets
were merged, a manual review of all patient records
was undertaken, and inclusion and exclusion criteria
were then applied.
Statistical methods
The mean adult population for each 1-year period was
used as the denominator (each person then equal to
one person year) for that respective year. Incidence
rates were presented as numbers per million person
years accompanied by 95% confidence intervals in pa-
rentheses. Statistical analyses were performed using
SPSS v.23 (IBM Corp., Armonk, NY, USA) and MS Excel
2010 (V14.0; Microsoft Corp. Redmond, WA, USA).
Categorical variables were presented as numbers and
percentages, where appropriate. Descriptive, continuous
variables with normal distribution were presented as a
mean with the corresponding range and standard
deviation. Statistical differences between groups for
non-parametric variables were calculated using the
Mann–Whitney U test and presented as exact P-values.
Trend lines were presented with an accompanying coef-
ficient of determination (R2).
Results
The adult population of Salford grew steadily from
172 984 to 191 083 persons over the 10-year period
between 2007 and 2016 (see supplementary data, avail-
able at Rheumatology online).
Case ascertainment
The inpatient ICD-10 coding search resulted in identifi-
cation of 922 cases. The search for new patients seen
in rheumatology and neurology outpatient neuromuscu-
lar clinics identified 201 cases. Review of the
UKMYONET database identified 33 cases resident in
Salford at the time of diagnosis. After removal of dupli-
cates, manual electronic record review and application
of the inclusion and exclusion criteria, 32 incident cases
of IIM were identified; 13/32 of these cases had biopsy
data. The resident persons ultimately deemed not to
have a diagnosis of IIM most commonly had inherited
myopathies, such as a dystrophy or a metabolic myopa-
thy, had episodes of rhabdomyolysis or had been incor-
rectly coded.
Incidence
The mean incidence of IIM in Salford throughout the
10-year study period was 17.6 (15.2–20.0)/1 000 000
person years. The incidence for females was higher than
for males; 25.2 (21.7–27.8)/1 000 000 vs 10.0 (8.4–11.7)/
1 000 000 person years, respectively. Stratifying cases
by calendar year, there was a trend towards increasing
annual incidence over the 10-year period (see Fig. 1).
Thus, when comparing pooled data for 2007–2011
against 2012–2016, there was a clear and statistically
significant increase in incidence over time [13.6
(11.5–15.7) vs 21.4 (18.3–24.5)/1 000 000 person years,
respectively; P¼0.032].
Clinical characteristics
Twenty-three of 32 incident cases were female. The
mean age at disease onset was 58.1 years (21–81;
S.D. 14.2). All but two cases had clinically apparent
myositis, and the additional extramuscular IIM
manifestations were broad. Ten of 32 had interstitial
lung disease, 9/32 a rash consistent with DM, 6/32 an
arthritis, 4/32 mechanic’s hands, 4/32 RP, and 3/32
had dysphagia. Three of 32 cases were associated
with cancer; these were all associated with a DM
subtype and were older than the remaining cohort
(mean age 70.3 years). Using EULAR/ACR criteria, the
largest subtype was PM (21/32), followed by DM
(8/32), IBM (2/32) and ADM (1/32). When subtype was
instead assigned by expert clinical opinion, the sub-
type frequencies for comparison were 5/32 PM, 6/32
DM, 2/32 IBM, 1/32 ADM, 9/32 anti-synthetase syn-
drome, 7/32 OM and 2/32 IMNM. Relevant patient-
specific clinical information used in clinical subtyping
is summarized in the supplementary data, available at
Rheumatology online. Figure 2 illustrates how
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individual cases classified using EULAR/ACR criteria
related to the clinically assigned subtype.
Discussion
The overall adult IIM incidence of 17.6 (15.2–20.0)/
1 000 000 person years sits within the range of estimates
from other national geographical regions. A systematic
review, summarizing the majority of these studies per-
formed across five continents, estimated the incidence
slightly higher than that described here at 20.0 (18.8–
21.3)/1 000 000 person years [2]. However, few of the in-
cluded studies used clinical or laboratory data to confirm
the case diagnoses, and only 4/46 studies reported adult
IIM subtype frequency. The last of these was published in
1999, therefore before the recent and rapid advances in
nomenclature and subtype characterization [7–10]. In
FIG. 1 The annual incidence of idiopathic inflammatory myopathies in the City of Salford, UK
Grey bars illustrate 95% confidence intervals; dashed green line illustrates linear trend line with accompanying coeffi-
cient of determination
FIG. 2 The relationship between EULAR/ACR classification criteria-assigned idiopathic inflammatory myopathy sub-
type and clinician-assigned idiopathic inflammatory myopathy subtype
ADM: amyopathic DM; ASS: anti-synthetase syndrome; IMNM: immune-mediated necrotizing myopathy; OM: overlap
myositis
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addition, the two largest studies reported the highest inci-
dences [42.7 (40.9–44.4) and 66 (62–69)/1 000 000 person
years, respectively], but identified cases solely on insur-
ance database ICD-9 coding systems [11, 12]. There is
considerable potential overlap in coding between IIM and
other muscular disorders, such as inherited myopathies,
dystrophies and metabolic myopathies, in addition to ac-
quired pathologies, such as non-immune-mediated rhab-
domyolysis, infections and alternative systemic
inflammatory conditions. This is supported by our data,
where our coding search identified 922 inpatient episodes
but, after manual review, all but 32 cases were non-IIM.
This systematic review thus concluded that coding
searches alone without additional medical record review
were likely to result in higher incidence and prevalence
estimates, with the consequence of potentially skewing
compound estimate figures. The present finding of a
higher incidence of adult IIM in females is a consistent
finding with all previous studies, except for some that fo-
cused on IBM and IMNM [2].
Two additional studies, published after the systematic
review, add to the context of our results. The study of
Svensson et al. [13] estimated an IIM incidence of 11
(10–12)/1 000 000 person years in a Swedish population.
This relatively low estimate might have been affected by
a single method of case ascertainment without manual
record review, and because the denominator population
was not restricted to the adult population alone. This
study also focused an ICD-10 search on two diagnostic
codes (M60.8 and M60.9) rather than the broader initial
coding search performed in our study and other studies.
Døbloug et al. [6] estimated an annual incidence of 6–
10/1 000 000 person years in a Norwegian population,
although this again did not report the incidence re-
stricted to adults. This study also excluded diagnoses of
IBM, ADM and OM, because these subtypes are not
specifically identifiable by the Targoff or Bohan and
Peter classifications [14, 15]. The relatively small number
of incident cases in our own study might have influ-
enced the overall estimate. However, whether the real
incidence of IIM is higher in Salford than in other
European populations is ultimately unclear.
Our data suggest an increasing incidence in adult IIM
over the 10-year period studied. One previous study has
demonstrated a statistically significant increase in IMNM
incidence over time, with this trend suggested to be the
result of a number of factors, including exposure to
statin medications, linked to the anti-HMGCR-antibody-
positive variant of IMNM [16]. Putative factors to explain
the observed temporal increase in IIM incidence include
improved awareness of IIM in the wider medical com-
munity and recognition of the extramuscular manifesta-
tions, which may present to a myriad of specialist
services, and improved access to and performance of
diagnostic procedures. That there might be a truly in-
creasing IIM incidence should be borne in mind when
future service development plans are being made.
The development of internationally accepted IIM clas-
sification criteria represents an important achievement.
However, it is important to bear in mind that these crite-
ria are likely to proceed through series of revision
changes over time. In particular, the incorporation of
more myositis-specific autoantibodies and IIM subtypes
not at present specifically included now appears neces-
sary. For instance, in our study, nearly 60% of the clini-
cal subtypes indicated by EULAR/ACR classification
would have been assigned differently by our clinical in-
terpretation, perhaps a reminder that classification crite-
ria are not designed primarily to be used in clinical
practice. Of potential relevance to this is the relatively
low number of cases (13/32) with biopsy data in our co-
hort. Given the invasive nature of the procedure, it is our
typical practice to avoid biopsy to confirm IIM diagnoses
in patients who already have a very high probability of
the diagnosis based upon their clinical and other investi-
gation findings. Our cohort contains a relatively high
proportion of patients with anti-synthetase syndrome
and OM (16/32), in whom we often feel biopsy is not
necessary for this reason.
Although relatively small, this study benefits from a ro-
bust, multimodal case ascertainment process, blending
methods from previous epidemiological studies. The
study also uses new classification criteria for the first
time in an IIM epidemiological study and allowed for de-
tailed clinical phenotyping as a result of manual review
of the medical records. Our study is limited by the pop-
ulation size, especially when considering the incidence
of individual IIM subtypes. We chose to focus upon the
City of Salford rather than, for example, the broader re-
gion of Greater Manchester, to ensure accurate case as-
certainment and more complete data acquisition. There
is always the potential for incomplete case acquisition in
studies similar to ours, for example in those IIM cases
with predominantly extramuscular manifestations not
recognized to have an IIM and where the introduction of
immunosuppression may prevent the evolution of the
phenotype to include more characteristic IIM features.
There is also the potential for patients who rapidly dete-
riorated with, for example, cancer-associated IIM or rap-
idly progressive interstitial lung disease and respiratory
failure, to be missed. However, we believe that the rou-
tine local practice of referring all suspected IIM to the
neuromuscular service, irrespective of predominant or-
gan involvement, in addition to the structure of primary
care referral pathways locally will have kept this to a
minimum. Conversely, there is also the potential for the
apparent increase over time to be partly or wholly
attributable to a catch-up phenomenon, whereby cases
that would have been missed 10 years ago are now be-
ing better identified, especially by non-neuromuscular
unit colleagues, because of advances in diagnosis and
local referral networks. Additionally, the clinical opinion
on subtype, and therefore the relative performance of
any classification criteria, is dependent on individual
Incidence of Idiopathic Inflammatory Myopathies
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interpretation of the current literature, which may vary
between clinicians.
Conclusion
The mean incidence of adult IIM in Salford is 17.6
(15.2–20.0)/1 000 000 person years; it appears to be in-
creasing over time and is in keeping with estimates from
other international studies. There remains disparity be-
tween clinician-attributed IIM subtypes and those
assigned by the recently developed EULAR/ACR classi-
fication criteria.
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